Abstract. New genomic technologies, such as exome, whole-genome and transcriptome sequencing, are transforming the genetic diagnosis of neuromuscular diseases and dramatically accelerating the discovery of new disease-associated genes. The increasingly widespread availability of these technologies creates both opportunities and challenges for neuromuscular disease researchers. Here we survey the current literature on the application of new genomic technologies to the diagnosis of severe muscle diseases, with a focus on assessment of the approaches used for data processing, analysis and interpretation. We also highlight several key areas requiring improvement.
INTRODUCTION
Next-generation sequencing (NGS) represents perhaps the most transformative technological advance in biomedical science since the development of the optical microscope. In less than a decade, the development and widespread adoption of short-read DNA sequencing has altered nearly every area of biomedical research, providing access to high-resolution biological data in areas ranging from DNA multiplex labeling for microscopy [1] to rapidly identifying pathogenic strains of E. coli during outbreaks [2] .
One area that has been particularly impacted by NGS is the diagnosis of rare diseases. As in other disease areas, genomic approaches have dramatically accelerated gene discovery and diagnosis in muscle diseases (Fig. 1 ). These technologies have been used to identify the genetic cause of three subtypes of domi- * Correspondence to: Monkol Lek, Tel.: +1 617 726 5936; Fax: +1 617 643 3293; E-mail: lek@atgu.mgh.harvard.edu. nant limb girdle muscular dystrophy (LGMD1D [3] [4] [5] , LGMD1F [6] , LGMD1G [7] ) that were localized by linkage analysis a decade ago. Similarly, it has identified the gene for Welander distal muscular dystrophy as a common cause of muscle disease in an isolated population [8] , which was also localized a decade ago. In addition, NGS has enabled researchers to identify the disease gene modifier, SMCHD1 in Facioscapulohumeral muscular dystrophy (FSHD) type 2 patients [9] that do not have the D4Z4 repeat contraction, which may shed light on non-manifesting carriers of this presumed pathogenic repeat contraction [10] . Also, two more genes from the Kelch-like (KLHL) family have been associated with nemaline myopathy [11, 12] .
In the field of rare genetic disease research, there are three broad approaches enabled by NGS technology. Due to cost-effectiveness the most commonly employed is whole exome sequencing, which involves the targeted capture and sequencing of the coding regions of the genome (i.e. exome). Also, targeted capture may be limited to gene panels in which complete 136 
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Fig. 1. The impact of Next Generation Sequencing in muscle disease gene discovery. The disease muscle disease genes were taken from the 2014 version of the gene table of monogenic neuromuscular disorders [75] . It was restricted to groups 1-5 and the first publication date the gene was identified.
and high coverage capture can be achieved and may be preferred in diagnostics to reduce false negatives. The next is whole genome sequencing, which provides a relatively unbiased survey of the genome including non-coding variants and structural variants. Lastly, RNA sequencing provides an unbiased survey of transcript isoform diversity provided by splicing. These technologies have been the subject of several recent reviews [13] [14] [15] [16] .
Genome and exome sequencing approaches provide several key advantages over traditional linkage/candidate gene approaches. Firstly, they can be used to discover genes in families with inheritance models inaccessible to linkage (such as de novo dominant diseases). Secondly, they overcome the "stopping problem" associated with serial testing of candidate genes in patients, in which a diagnosis is provided based on the first compelling candidate variant identified in a tested gene, rather than the most compelling variant across all genes. Finally, NGS has empowered researchers to comprehensively study very large genes -common among muscle disease genes -that are largely inaccessible with traditional approaches (Table 1) .
Exome sequencing is a powerful approach that allows researchers to identify vast numbers of potential candidate mutations. However, this power also brings a major challenge: with hundreds of rare, potentially functional variants in every genome, it can be all too easy to build a compelling but false story about causal variants, a problem referred to as the "narrative potential" of human genomes [17] . To address this challenge a US National Human Genome Research Institute working group was formed to discuss this challenge and recently published guidelines for implicating sequence variants to disease [18] .
In this review we survey the current literature on the application of genomic technology to gene discovery in neuromuscular diseases ( Table 1 ). The manuscripts included in this survey were from a PubMed search of the keywords "muscle" and "exome sequencing". This list was then reduced by removing cardiomyopathies and Walker-Warburg syndromes. Thus the review does not aim to be fully comprehensive including all novel genes and mutations discovered but rather a survey to assess the degree in which selected studies empowered by exome sequencing conforms to best-practice standards. A secondary aim is to review overall informatics workflows with a focus on under-appreciated aspects of these workflows.
NGS INFORMATICS PIPELINE/ WORKFLOWS
The majority of publications reporting new neuromuscular disease genes document the method, tools and resources used for exome sequencing analysis (Table 1) . In high impact publications, space limitations mean that such details are often consigned to the supplementary methods, and they can sometimes be entirely omitted from brief case reports. Moving from raw NGS data to interpretable variant calls requires a number of critical steps to be performed. Firstly, raw sequencing reads are aligned to the reference genome, and additional processing and calibration steps performed to improve these alignments. For the mapping of reads, the freely available tool, Burrows-Wheeler Aligner (bwa) is the most widely used tool in the study surveyed. In addition, missing from Table 1 are commonly used tools/options Picard, Genome Analysis Toolkit (GATK) and samtools in pre-processing prior to variant calling. Secondly, the aligned reads at each position along the reference are scanned for evidence of a variant -a location at which the individual differs from the reference sequence, either in the heterozygous or homozygous state. Variants are then scored with statistical confidence, and filtered to remove systematic artifacts. Amongst reviewed muscle research, GATK and samtools were the most popular variant callers for this step. Furthermore, GATK is more widely used due to its user friendly but powerful variant filtering. As each of these steps can be performed using a range and combination of different informatic tools, making Careful reporting of methods is critical for NGS applications, since tools and resources for NGS are in constant development, including new software versions as well as updates to resources such as the human genome reference sequence (http://www.ncbi.nlm.nih.gov/projects/genome/assem bly/grc/human). In addition, choice of gene models for annotation [19] and subtle differences in workflows can result in large discrepancies in variant discovery [20] . There have been many comprehensive reviews on workflows and quality control in the context of rare diseases [14, 17, 21 ] and more specifically rare muscle diseases [22] [23] [24] [25] [26] [27] [28] , therefore this section will focus on under appreciated but important themes within sample validation, quality and computational requirements.
Sample quality control
A critical step before proceeding to variant interpretation is quality control. The presence of family data in many rare disease studies provides a valuable resource for quality control, since it can be used to identify Mendelian violations such as de novo mutations and transmission errors, as well as discordance between inferred and expected pedigree structures (see below). Other valuable quality metrics can also be directly inferred from sequence data, such as transition to transversion ratio (TiTv), insertion to deletion ratio and total number of variants per sample, all of which can be compared to previous reference samples to identify gross problems with sequence quality. The data from next generation sequencing, similar to other experiments, is also at risk of sample contamination (the accidental mixture of samples from different sources) even when extreme care is taken in each step of the workflow. The tool verifyBAMID [29] , which samples across many common SNPs, is one widelyused method for assessing such contamination directly from sequence data. The Genome Analysis Toolkit (GATK) assumes samples have 0-5% contamination and can reliably correct genotype calls for samples with up to 10% contamination.
In targeted gene sequencing there are very few common variants discovered in each sample; in contrast, exome sequencing allows the discovery of thousands of common variants across genes. These common variants or a subset then can be used as a means to identify samples and also infer relationship between samples [30] . First, using identity by descent metrics calculated by PLINK [31] , we can confidently infer first and second degree relationships between samples. This is particularly useful in pedigree study designs in identifying duplicate samples, non-paternity and accidental sample mislabeling. Second, these variants can be used to estimate the deviation from expected heterozygosity represented as inbreeding coefficient (F). A significantly negative inbreeding coefficient (i.e. higher than expected heterozygosity) suggests a sample may be contaminated, while a positive F may suggests a sample is a child from consanguineous parents. Interestingly, high heterozygosity in contaminated samples will make them appear to be related to all samples [31, 32] . Thirdly, heterozygosity of common variants on chromosome X can be used to infer the gender of the sample. In addition, normalized coverage of chromosome X and Y can also be used to infer gender [32] . Lastly, common variants from samples can be used in a principle component analysis with samples of known ethnicity (eg. 1000 genomes samples [33] ) to infer ethnicity of samples (Fig. 2) . The latter two methods is particular useful for consistency checking in cases where only the proband was sequenced. The correct labeling of samples is absolutely crucial for the discovery of candidate mutations and the above techniques highlight how data from exome sequencing can be used to infer labeling inconsistencies. Also, early discovery of inconsistencies can save time and resources.
Sequencing coverage
Generating sufficient and uniform coverage across muscle disease genes is a challenge due to their overall size, number of exons, high similarity, low sequence complexity and high GC content [24] [25] [26] . Although within-sample coverage across genes is important, consistent coverage across samples is equally important in pedigree study designs. For example, in samples with highly variable coverage, there will be many cases where there is inadequate coverage for a candidate mutation across some members in the pedigree. Variable coverage becomes an even greater problem when samples from the same pedigree are sequenced at different sequencing centers. The coverage metric is a proxy to infer the ability to call variants at a site but does not take into account the quality of the sequencing reads and confidence of the mapping to a location in the genome, therefore a better metric would be the callability of a site, which takes base quality into account. There are regions in TTN and NEB where exons are almost identical, making it difficult for the short reads from NGS to be mapped confidently. Another difficult region is the gene clusters containing MYH2, MYH7 and including other myosin (MYH) genes. The genes in this cluster have been duplicated multiple times and some exons in each gene are still highly similar between genes. Lastly, genes such as ACTA1, TPM2 and FLNC have pseudogenes scattered across the genome that can have off-target reads mapped to them. In the case of FLNC this has resulted in erroneous mutation reports [34] . Due to these challenges some researchers have preferred targeted gene capture panels or supplementation by traditional Sanger sequencing over poorly covered regions [26, 28] . However, despite these challenges the last two years have shown an increase in mutation reports in TTN and MYH7 ( Table 1 ), genes that have been challenging using traditional approaches.
Active storage costs
A typical high coverage exome fills approximately 8-20 Gb of hard disk space, which is a substantial increase from data usage required for Sanger sequencing of genes. Furthermore, 30x coverage whole genome sequenced samples can require up to 500 Gb of storage. The secure storage and transfer of this data is a huge challenge faced by researchers, for which most labs are inadequately prepared in terms of IT infrastructure. Many researchers also underestimate the substantial costs associated with the storage and processing of raw data from NGS, as well as intermittent re-processing as new algorithms become available. The development of compressed representation of NGS data as gVCFs and CRAM (compressed BAM) remains an active area of research with substantial potential to both reduce storage and processing costs. While whole genome sequencing now approaches the long-fabled $1000 target, lowering the costs of storage, processing and interpretation remains a challenge.
LIMITATIONS OF EXOME SEQUENCING
The overall success of exome sequencing in cohorts of undiagnosed muscle diseases is difficult to estimate due to widespread ascertainment and publication bias; in other rare diseases, success rates hover between 15 and 40% [35] . Discussed in this section are two broad areas of improvement: extracting full use of a patient's exome sequencing data and then possibly supplementing with other genomic technologies.
Study design
The study design for undiagnosed families is a compromise between cost and increasing genetic evidence. Starting with a proband-only approach will identify patients with known muscle disease mutations that were missed during screening and also identify strong gene candidates that are common amongst probands with a similar phenotype. If there are no strong candidate mutations, parents and additional family members can then be sequenced. There are notable limitations to this proband-first approach. Firstly, the timely results for some probands may be required for important medical or family planning decisions and therefore additional family members are usually sequenced. It is usually not possible in the case of recessive inheritance to determine if two mutations in a proband segregate with the disease (i.e. are compound heterozygous), or if candidate dominant mutations have arisen de novo in the proband, and there may be too many candidates to confirm using Sanger sequencing. Similarly, unless very fine mapping has been performed, probands with suspected dominant inheritance will often have large numbers of candidate mutations. Also, as discussed in the previous section, having no additional family members limits the ability to detect sample mislabeling and other inconsistencies. Lastly, sequencing additional family members in a different batch may result in batch artefacts and also reduces the sensitivity of tools such as copy number variant (CNV) detection.
Variant annotation
The choice of annotation tool and gene models can result in various discrepancies and has an unappreciated impact on our ability to interpret sequence variants [19] . The majority of mutations reported in recent neuromuscular disease gene discovery papers have been missense or truncating mutations caused by nonsense or frame shift mutations. Interestingly, in the case of FDX1L there was a start loss mutation rescued by a nearby methionine but resulting in lower protein levels [36] . Also, TPNO3 has a stop loss mutation and depending on isoform involves an extension of 15 or 95 amino acids resulting in mislocalization [6] . The majority of publications do not explicitly mention the use of splice prediction for variants outside the essential donor and acceptor splice sites. Although, some capture kits target promoter and untranslated regions (UTRs) our ability to interpret is still limited. The recently characterized homozygous 9 bp deletion in the promoter of POMGNT1 causing transcription repression is one such mutation that may be missed [37] . Lastly, another limitation is the correct annotation of multiple nucleotide polymorphisms (MNPs), which occurs when variants in the same codon are on the same haplotype and should not be treated as two independent annotations. This may result in missense variants annotated as loss of function [38] .
Structural variant detection
In the studies reviewed, structural variants have not been implicated with muscle disease partly due to the challenges in detecting this class of variation in exome sequencing. Within the DMD gene, large deletions or duplications account for 74% and 87% of the total mutations in Duchenne muscular dystrophy and Becker's muscular dystrophy, respectively [39] . There currently is no comprehensive survey of structural variants in a large neuromuscular disease cohort. As a comparison, conclusive de novo CNVs account for 21% of cases in a severe intellectual disease cohort [40] . These copy number variations can be detected by analyzing significant read coverage deviation using tools such as exomeDepth [41] and XHMM [42] but there is still much room for improvement. The main challenge is distinguishing a read coverage deviation caused by true copy number and those caused by sample preparation, sequencing efficiency and read mapping. Using an appropriate reference panel that has been processed by the same workflow can help reduce false positives. Similarly, variant calling is difficult in short tandem repeat (STR) regions where there can be benefits in using specialized tools such as lob-STR [43] . The challenges with detecting variants in the STR region are that only a proportion of short reads will span the entire region and the PCR amplication used in sample preparation is prone to slippage in these regions. Lastly, retrotransposon insertion in FKTN, POMT1 and DMD are known to cause muscle disease [44] . A systematic survey of mobile insertion in the 1000 genomes project has outlined how these events can be robustly detected [45] , however in exome sequencing there may not be enough sequencing reads to convincingly support this event.
There are various structural variants that are difficult to detect using next generation sequencing but are known to occur in muscle diseases. Both myotonic dystrophies involve expansions of tandem repeats, in myotonic dystrophy (DM1) there is a expansion of CTG repeats in the 3 UTR of DPMK [46] , while in myotonic dystrophy (DM2) there is expansion of CCTG in intron 1 of ZNF9 [47] . The contraction of D4Z4 repeat units in sub-telomeric region of chromosome 4 results in FSHD [48] . The insertion of SVA retrotransposon in the FKTN 3 UTR causing Fukuyama-type congenital muscular dystrophy (FCMD) was the first human disease reported to be associated by this mechanism [49] . The SVA insertion results in a modified FKTN C-terminus affecting protein localization. Due to the common occurrence of DM1/2, FSHD and FCMD (amongst Japanese population), these mutations should be screened using more sensitive assays for patients with similar phenotypes.
Whole genome sequencing
The reducing costs of next generation sequencing will lead to wider use of RNA sequencing and whole genome sequencing. At the moment variants detected from whole genome sequencing are greatly limited by our ability to annotate and interpret non-coding sequence variants and there is also limited high coverage reference genomes to compare results. Apart from structural variants and known functional sites, ironically analysis is typically limited to genic regions of the genome. For instance, we note that an early publication demonstrating the use of genome sequencing for the diagnosis of Charcot-Marie-Tooth Neuropathy could have been successfully replicated using exome sequencing [50] .
RNA sequencing
RNA sequencing is an orthogonal approach that addresses some key limitations in interpretation. It will allow us to detect the impact of expression and splicing in RNA isolated from disease muscle and in combination with DNA sequencing data will allow us to associate variants to these events. As a new and emerging technology there are several challenges associated with RNA sequencing. Firstly, informatic workflows are not as well-established as for DNA sequencing technologies, with little current consensus about bestpractice workflows. Secondly, the process of obtaining RNA from primary muscle requires an invasive muscle biopsy, limiting its applicability. Fortunately, existing muscle biopies that have been stored properly are usually adequate for RNA sequencing. Thirdly, it is unclear what sequencing coverage is required to adequately detect pathogenic alterations. Finally, the large size of muscle genes combined with the bias of RNA sequencing data generated using standard poly(A) capture protocols towards the 3 end of transcripts can substantially reduce coverage of the 5 ends of many known muscle disease genes.
GENETIC EVIDENCE
In all reviewed publications, the minimum evidence presented was Sanger sequencing validation of the candidate mutation and segregation of this mutation amongst affected and unaffected available family members; linkage analysis was also typically performed for dominant diseases. In the case of novel disease gene association, mutations were discovered in multiple unrelated families except for the case of CCDC78, HACD1 and FDX1L.
Large, publicly available data-sets of population control sequencing data have been rapidly adopted as a standard part of NGS analysis protocols by most muscle disease researchers, providing much more precise estimates of variant frequency than the traditional 100-200 control chromosomes. The majority of publications reviewed used variants from dbSNP, Exome Variant Server (http://evs.gs.washington.edu/EVS) and the 1000 Genomes Project to filter out variants in exomes. Interestingly, these data sets have empowered the development of frameworks to identify genes that are constrained [51] or intolerant [52] to mutation. These frameworks can be used to assess mutations in large genes such as TTN and NEB that are more likely to have rare variants by chance. Lastly, a variant that is absent or rare in population controls should not be used as the only evidence to conclude pathogenicity in a known disease gene. As more reliable and relevant high-throughput functional assays are developed, these assays can be employed with "saturation editing" to assess all possible variations of interest for a desired gene [53] .
There are several limitations that muscle researchers should bear in mind when using these public resources. The variants within dbSNP are not limited to benign variants and also contain pathogenic mutations. The Exome Variant Server (EVS) hosts variants from the NHLBI GO ESP cohort, which contains individuals with various forms of cardiovascular disease and is limited to European Americans and African Americans. Although, the 1000 Genomes Project represents a more global cohort, the representation of various population groups is very limited in number [33] . Lastly, the public resources have not been processed and analyzed in the same way as the patient exomes, which may contribute to artefactual differences. To address these limitations, some of the studies have used appropriate population controls and also "in house" control exomes.
INFORMATIC SUPPORT
The use of pathogenicity prediction was reported in almost all missense variants in the publications reviewed. The most common prediction tools were SIFT [54] , Polyphen2 [55] and Mutation taster [56] . These predictions should not be treated as independent as they are trained on similar data sets with overlapping training parameters. The recently available Combined Annotation-Dependent Depletion (CADD) method has attempted to address some of the limitations of previous tools including scores for non-coding variants and small insertion-deletions [57] . In contrast, splicing prediction was rarely employed; for proposed splice-disrupting mutations direct experimental evidence was presented instead. Lastly, molecular modeling using FoldX [58] and visualization using PyMOL (http://www.pymol.org) was presented in nemaline myopathy studies [12] , where similar proteins structures are available for candidate genes.
The use of publicly available RNA expression and protein-protein interaction data was not widely reported by the studies reviewed. The pilot phase of the Genotype and Expression (GTEx) project has RNA sequencing from various human tissues [59] , including skeletal and cardiac muscle. The expression data is publicly available through the GTEx portal (http://www.gtexportal.org) and can be used to address muscle tissue expression and whether candidate mutations are in muscle expressed transcripts. There are plans to expand the range of tissues, including multiple muscles with disease relevance. The differential expression patterns between muscle groups may help to explain the known difference in muscle wasting patterns amongst the muscle diseases [60] . There are numerous manually curated protein-protein interaction databases and also a recently published LGMD specific protein interaction network [61] . Using available tools such DAPPLE [62] , new candidate genes can be tested for their association with other known disease proteins in the network. The use of these publicly available resources will reduce the need to present results from tissue expression experiments, however the under-representation of developmental isoforms is an obvious limitation of using these data.
EXPERIMENTAL EVIDENCE
All studies have comprehensively characterized a subset of affected patients and, in the case of novel genes, established the expression and protein localization in muscle and other relevant disease tissues. In implicating novel candidate genes, a subset of studies used morpholino knock down in zebra fish. Furthermore, in the case of KLHL41 [12] and DNAJB6 [3] the knock down phenotype was rescued using mRNA from the human gene, ruling out the possibility that the phenotype was due to off target effects of the morpholino. Interestingly, the disease mechanism of FSHD2 is primate specific due to the interaction between SMCHD1 and the D4Z4 repeat units [9] . Although there is a mouse model, it fails to recapitulate any of the muscle phenotype observed in human patients [63] . Besides zebra fish, no other animal models were used, thus showing the appeal of zebra fish models in obtaining rapid muscle disease phenotype results. Although zebra fish modeling is a path to more rapid publication, researchers must remain prudent that mouse models are more similar to human muscle function and also the complications introduced by duplicate functional gene copies in the zebra fish. In some studies, experiments on patient samples/mutations included a combination of disease specific functional assays (eg. enzymatic activity for mutations in genes that encode enzymes), splicing assays, protein mislocalization, truncation and reduced protein levels.
PUBLIC SHARING AND REPORTING
The correct reporting of disease variants and sharing of exome sequencing data would greatly empower muscle disease research and effectiveness of diagnostic labs around the world. There are two widely used free mutation databases for muscle researchers, the Leiden muscle dystrophy database (http://www.dmd.nl) and ClinVar [64] . In addition, exome and phenotype data can be stored on European Genome-phenome Archive (EGA) or the database of Genotypes and Phenotypes (dbGaP). Both dbGaP (http://www.ncbi.nlm.nih.gov/gap) and EGA (https://www.ebi.ac.uk/ega/home) are public archives for storing genotype and phenotype data in a structured format and also having a mechanism to approve other researchers to access the data. In the reviewed studies, a few mutations discovered have been previously reported [65] [66] [67] [68] [69] . Given, the existing reported mutations are known to include benign variants some scrutiny should be applied based on evidence demonstrated in the original report. Unfortunately only a few studies have explicitly stated the reporting of mutations in a public database [8, 70, 71] and only exomes sequenced from UK10K are available through EGA [71] [72] [73] . For our own research, muscle disease samples sequenced at the Broad Institute have been made available to the research community through dbGaP as the Genetics of Inherited Muscle Disease (Study Accession: phs000655.v1.p1). Two publications have already resulted from this cohort [72, 74] . Since its release in December 2013, it has been requested by 8 research groups and will be used for the development of better analytical techniques and tools in not only the domain of rare muscle diseases but also common diseases and cancer.
There are a few broad areas that researchers in the muscle disease community can improve upon on this front. First, locus-specific databases such as the Leiden muscular dystrophy database have assigned curators for each gene, but publication authors should also take responsibility for reporting and maintaining mutation reports; this effort will likely soon shift towards ClinVar, which we believe is emerging as the likely primary global repository of disease-causing variants. Furthermore, variants need to be carefully labeled with the evidence supporting pathogenicity, as outlined in several recent publications [18, 21] .
Researchers must also face up to the perverse incentives against data sharing created by the current academic publication system. Many newly discovered genes languish for months or even years between confident identification and formal publication, while authors accumulate the additional families and experimental support required for a high-impact publications; this delay does a disservice to patients and their families. In addition, even after publication, many reports are locked behind journal subscription paywalls, hindering access by patients and their families. Given the value of this access to patients, and the generous donation of patient time and samples to the research process, we believe the research community has a moral imperative to improve this access, and urge researchers to favor open access publications, and to consider making their pre-formatted manuscripts available prior to publication through preprint servers such as bioRxiv (http://biorxiv.org).
Finally, we emphasize that sharing is greatly empowered by consistent nomenclature. The majority of publications reviewed did not use genomic coordinates and instead have used HGVS nomenclature, which is transcript-specific and frequently ambiguous.
The rapid increase of subtle subcategories of phenotypes [75] have called for the use of more consistent description of phenotypes; formal structured vocabularies such as the Human Phenotype Ontology [76] and interface frameworks such as PhenoTips [77] will help to increase consistency. Lastly, there is a publication bias towards diagnosis in exome sequencing, with very few published unsolved cases. As a community we need to establish frameworks to make genetic data from unsolved cases available to collaborators to empower joint analysis with other cohorts. The RDConnect platform used by the NeurOmics project is an example of such a framework [78] .
CONCLUSIONS
New genomic technologies are unquestionably changing the landscape of rare disease genetics. While some challenges remain in terms of accuracy, especially for insertion and deletion variants, raw sequencing data is becoming increasingly accurate and complete; we expect that with increasing sequence accuracy and the advent of longer-read sequencing technologies most regions of the human genome will soon be fully accessible. However, major challenges remain to be resolved before NGS approaches can become a fully mature diagnostic toolkit. The most formidable of these challenges remain in the field of variant interpretation: taking the hundreds of rare, potentially functional variants in any individual's genome and confidently identifying the handful of variants that underlie a specific disease phenotype in that individual. Achieving perfect diagnostic rates for rare diseases will require consensus-building on standards for assessing variant pathogenicity; greatly improved statistical approaches for differentiating disease-causing variants from benign "noise"; and a strong commitment to data sharing, both before and after publication.
